Estradiol Valerate vs Ethinylestradiol in Combined Oral Contraceptives: Effects on the Pituitary-Ovarian Axis
article
OA: bronze
CC0
⤵ 1 in-corpus citation
AI-generated summary
Combined oral contraceptives with estradiol valerate and dienogest suppressed FSH less than ethinylestradiol and dienogest, while both formulations similarly decreased AMH.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
CONTEXT: Limited studies have compared the effects of combined oral contraceptives (COCs) containing natural estrogens and synthetic ethinylestradiol (EE) on reproductive hormones. OBJECTIVE: To compare estradiol valerate (EV) + dienogest (DNG), EE + DNG, and DNG alone (active control) on levels of follicle stimulating hormone (FSH), luteinizing hormone, anti-Müllerian hormone (AMH), ovarian steroids, sex hormone binding globulin (SHBG), and the free androgen index (FAI). METHODS: This spin-off study from a randomized trial enrolled 59 healthy, 18 to 35-year-old ovulatory women, outpatients at Helsinki and Oulu University Hospitals, Finland, who were randomized to EV 2 mg + DNG 2-3 mg (n = 20); EE 0.03 mg + DNG 2 mg (n = 20); and DNG 2 mg (n = 19) for 9 weeks. Blood samples were drawn at baseline, and at 5 and 9 weeks. Age and BMI were comparable between groups; 3 women discontinued. RESULTS: EV + DNG suppressed FSH by -27% (-51% to -3%) (median [95% CI]) vs EE + DNG, -64% (-78 to -51), P = 0.04, but AMH levels decreased similarly by -9% (-18 to -0.1) vs -13% (-28 to 0.2), P = 0.38, respectively. EV + DNG increased SHBG levels by 56% (30% to 82%) and EE + DNG by 385% (313% to 423%), P < 0.001. Total testosterone decreased by 16% (-27% to -5%) in the EV + DNG group but it did not decrease in the EE + DNG group, whereas the FAI decreased by -39% (-54% to -25%) vs -72% (-78% to -67%), P < 0.001. DNG alone did not induce changes in any of these parameters. CONCLUSION: Compared with EE + DNG, treatment with EV + DNG resulted in milder pituitary downregulation and reduced induction of hepatic SHBG synthesis-potentially carrying more beneficial health effects.
My notes (saved in your browser only)
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (65)
- Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? via openalex
- Dienogest via openalex
- Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism via openalex
- Effects of an oral contraceptive containing estradiol valerate and dienogest on circulating androgen levels and acne in young patients with PCOS: an observational preliminary study via openalex
- Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): A Phase III trial via openalex
- Impact of estrogen type on cardiovascular safety of combined oral contraceptives via openalex
- Influence of Dienogest on Ovulation in Young Fertile Women via openalex
- Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain via openalex
- Metabolic and Haemostatic Effects of Estradiol Valerate/Dienogest, a Novel Oral Contraceptive via openalex
- Ovulation‐Inhibiting Effects of Dienogest in a Randomized, Dose‐Controlled Pharmacodynamic Trial of Healthy Women via openalex
- Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest via openalex
- Preliminary Study on the Effect of Four-phasic Estradiol Valerate and Dienogest (E2V/DNG) Oral Contraceptive on the Quality of Sexual Life via openalex
- Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial via openalex
- doi:10.1016/s0140-6736(80)91550-0 via openalex
- doi:10.1016/j.ajog.2005.12.007 via openalex
- doi:10.1007/s11154-011-9182-4 via openalex
- doi:10.1016/0002-9378(77)90295-2 via openalex
- doi:10.1111/j.1538-7836.2012.04720.x via openalex
- doi:10.1111/jsm.12310 via openalex
- doi:10.1016/j.rbmo.2012.09.001 via openalex
- doi:10.1016/0378-5122(82)90064-0 via openalex
- doi:10.1080/13697130500148875 via openalex
- doi:10.1046/j.1365-2141.2003.04443.x via openalex
- doi:10.1093/humrep/deh612 via openalex
- doi:10.3109/13625187.2011.614363 via openalex
- doi:10.1016/j.cca.2007.07.013 via openalex
- doi:10.1016/s0002-9378(03)00950-5 via openalex
- doi:10.1093/humupd/dmt038 via openalex
- doi:10.1210/jcem.84.10.6079 via openalex
- doi:10.1016/j.thromres.2010.01.045 via openalex
- doi:10.1080/13625187.2019.1702158 via openalex
- doi:10.1111/1471-0528.16840 via openalex
- doi:10.1016/j.ajog.2021.06.052 via openalex
- doi:10.1016/j.contraception.2017.01.001 via openalex
- W6676115632 via openalex
- doi:10.1093/humrep/dev197 via openalex
- doi:10.1016/j.fertnstert.2021.02.007 via openalex
- doi:10.1530/eje-20-0406 via openalex
- doi:10.1097/01.aog.0000559087.93476.bc via openalex
- doi:10.1016/j.contraception.2020.10.014 via openalex
- doi:10.1111/jsm.12774 via openalex
- doi:10.1002/ijgo.12455 via openalex
- doi:10.1016/j.jsxm.2019.08.005 via openalex
- doi:10.1093/humupd/dmt062 via openalex
- doi:10.1182/blood-2003-04-1285 via openalex
- doi:10.3109/13625187.2015.1044082 via openalex
- doi:10.1016/j.contraception.2020.08.015 via openalex
- doi:10.3109/13625187.2010.504313 via openalex
- doi:10.1056/nejmoa1111840 via openalex
- doi:10.1080/13625187.2021.1988923 via openalex
- doi:10.1080/13625187.2021.1987410 via openalex
- doi:10.2165/11591200-000000000-00000 via openalex
- doi:10.1016/j.contraception.2012.12.011 via openalex
- doi:10.1016/j.contraception.2008.05.004 via openalex
- doi:10.15761/fwh.1000175 via openalex
- doi:10.1089/jwh.2016.5801 via openalex
- doi:10.1210/clinem/dgaa513 via openalex
- doi:10.1016/j.contraception.2012.07.008 via openalex
- doi:10.3109/00016348509157028 via openalex
- doi:10.1016/s0010-7824(02)00436-5 via openalex
- doi:10.1016/j.maturitas.2012.01.018 via openalex
- doi:10.1016/j.fertnstert.2012.11.034 via openalex
- doi:10.1016/0002-9378(82)90218-6 via openalex
- doi:10.1002/14651858.cd010813.pub2 via openalex
- doi:10.1093/humrep/des225 via openalex
Cited by (1)
Source provenance
- openalex
- last seen: 2026-05-14T06:40:32.549041+00:00
License: CC0
· commercial use OK